Allergic contact dermatitis caused by contact with lacquer sap and lacquerware affects the welfare of lacquer workers and the lacquerware industry. Many studies of the mechanism of urushiol allergy, including animal models, have been carried out and have established several hypotheses. In order to provide a comprehensive understanding of lacquer allergy, we review recent advances in the research on lacquer allergy including the chemical properties of lacquer lipid components, allergic mechanism analyses, immunological explanations, allergy medications, and the prevention combined with the research results from our laboratory.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2332/allergolint.11-RA-0324 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eyelid Dermatitis: Common Patterns and Contact Allergens.
Cutis
October 2024
Mykayla Sandler and Dr. Yu are from the Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston. Ivan Rodriguez and Dr. Adler are from the Keck School of Medicine, University of Southern California, Los Angeles. Dr. Adler is from the Department of Dermatology.
Article Synopsis
- - Eyelid dermatitis is a prevalent skin condition characterized by inflammation, with allergic contact dermatitis (ACD) being the most common cause, triggered by exposure to allergens.
- - Common allergens linked to eyelid dermatitis include metals, fragrances, preservatives, and certain medications found in cosmetics and everyday products.
- - Effective treatment focuses on avoiding allergens and includes patient education on recognizing triggers; the review also covers signs, evaluation methods, and patch testing for diagnosis.
Occupational Contact Dermatitis in Construction Workers: A Retrospective Analysis of the North American Contact Dermatitis Group Data, 2001-2020.
Dermatitis
September 2024
Division of Dermatology, University of Ottawa, Ontario, Canada.
Construction workers (CWs) are at risk for occupational contact dermatitis (CD) owing to workplace exposures. Determine the prevalence of occupational allergic CD and characterize common occupational allergens in CWs referred for patch testing in the United States and Canada. Retrospective cross-sectional analysis of patients patch tested by the North American Contact Dermatitis Group from 2001 to 2020.
View Article and Find Full Text PDFPhase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
N Engl J Med
October 2023
From Johns Hopkins Itch Center, Johns Hopkins University School of Medicine, Baltimore (S.G.K.); the Miami Itch Center, Miller School of Medicine at the University of Miami, Miami (G.Y.); the Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria (F.J.L.); the Department of Dermatology, University of Rzeszow, Rzeszow (A.R.), and the Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw (J.C.S.) - both in Poland; the Department of Dermatology, Medical University of Toulouse, Toulouse (C.P.), the Department of Dermatology, University Hospital, Nantes (S.B.), and the Department of Dermatology, University Hospital of Brest, Brest (L.M.) - all in France; the Department of Dermatology, Bern University Hospital, Bern (D.S.), the Department of Dermatology, Lausanne University Hospital CHUV and University of Lausanne, Lausanne, (C.C.), and Galderma, Zug (Z.K.J.L., C.P.) - all in Switzerland; the Academic Research Center, Centro Studi GISED, Bergamo, Italy (L.N.); the Lynde Institute for Dermatology & Lynderm Research and the Division of Dermatology, Department of Medicine (C.L.), University of Toronto, Toronto (C.L., M.S.); the Department of Dermatology and Allergology, Utrecht University-UMC, Utrecht, the Netherlands (M.S.D.B.-W.); the University Dermatology Group, University of California, San Diego, San Diego (W.K.N.), and First OC Dermatology Research, Fountain Valley (V.T.L.) - both in California; West Virginia Research Institute, Morgantown (R.G.); the Department of Dermatology, University of Cincinnati College of Medicine, Cincinnati (A.F.); Hospital de la Santa Creu i Sant Pau, Barcelona (E.S-B.); the Department of Dermatology, Ghent University Hospital, Ghent, Belgium (H.L.); Galderma R&D, Dallas (F.A.); and the Center for Chronic Pruritus, University Hospital, Munster, Germany (S.S.).
Article Synopsis
- Prurigo nodularis is a chronic skin disease causing intense itching, and nemolizumab, an IL-31 receptor antagonist, targets its underlying mechanisms.* -
- In a phase 3 trial, 274 adults with moderate-to-severe prurigo nodularis were given nemolizumab or a placebo for 16 weeks, showing significant improvements in itch and overall skin condition.* -
- Results revealed that 56.3% of the nemolizumab group reported reduced itching compared to 20.9% in the placebo group, with similar trends observed for other secondary outcomes, demonstrating its efficacy (P<0.001).*
Zn @Polyvinylpyrrolidone and Urushiol Preparation of Nanofibrous Membranes and Their Synergistic Effect.
Macromol Biosci
November 2023
Fujian Key Laboratory of Novel Functional Fibers and Materials, Minjiang University, Fuzhou, Fujian, 350108, China.
In this study, lacquer is gathered from a lacquer tree and rotary evaporation is used to remove impurities to obtain urushiol. Next, 10 mL of anhydrous ethanol serves as the solvent for blending polyvinylpyrrolidone (PVP) at a specified content (0.7 g and 0.
View Article and Find Full Text PDFSafety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Dermatol Ther (Heidelb)
July 2023
Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
Article Synopsis
- Atopic dermatitis (AD) is a chronic skin condition with few treatment options for teens, and lebrikizumab, an antibody targeting IL-13, shows potential benefits in treating it, based on previous studies.
- The Phase 3 ADore study involved 206 adolescents with moderate-to-severe AD, who received lebrikizumab and were monitored for safety and effectiveness over 52 weeks.
- Out of 172 participants who completed the study, many experienced improvements, such as 65% achieving significant reductions in disease severity, while serious side effects were infrequent, indicating the treatment's promise for managing AD in adolescents.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!